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Abstract
Objectives—Prompt treatment for lupus is important to prevent morbidity. A potential barrier to 
early treatment of pediatric lupus is delayed presentation to a pediatric rheumatologist. To better 
understand factors contributing to delayed presentation among pediatric lupus patients, we 
examined differences in demographic and clinical characteristics of lupus patients within the 
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry with regards 
to time between symptom onset and presentation to a pediatric rheumatologist.
Methods—We analyzed data from 598 CARRA Legacy Registry participants for differences 
between those who presented early (within <1 month of symptom onset), between 1–3 months 
(typical presentation), with moderate delays (3–12 months), and with severe delays (≥1 year). 
Factors associated with early presentation, moderate delay, and severe delay, were determined by 
multinomial logistic regression.
Results—Forty-four percent of patients presented early, while 23% had moderate delays and 9% 
had severe delays. Family history of lupus, absence of discoid rash and location in a state with a 
higher density of pediatric rheumatologists was associated with earlier presentation. Younger age, 
low household income (<$25,000 per year), and a family history of lupus were associated with 
severe delay.
Conclusions—Delays to care ≥ 1 year exist in a notable minority of pediatric lupus patients 
from the CARRA Legacy Registry. In this large and diverse sample of patients, access to care and 
family resources played an important role in predicting time to presentation to a pediatric 
rheumatologist.
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INTRODUCTION
Early detection and treatment is thought to be critical to prevent morbidity and improve 
outcomes in both adults (1–3) and children (4, 5) with lupus. While the time to diagnosis for 
lupus patients has improved over the past several decades (6), significant delays still exist 
(7). Prompt management may be challenging for patients with rheumatologic diseases given 
widespread shortages in rheumatology practitioners and the difficulty in recognizing and 
diagnosing many of these relatively rare disease entities (8–10). Delayed diagnosis and 
presentation to a rheumatologist has been described worldwide in some of the most common 
adult rheumatologic diseases, such as rheumatoid arthritis (11) and psoriatic arthritis (12), as 
well as the more common pediatric rheumatologic diseases, such as juvenile idiopathic 
arthritis (13–15).
Diagnosing rheumatologic diseases in children and quickly connecting them to specialist 
care is likely more challenging than in adults. Shortages of pediatric subspecialists are more 
profound than of adult subspecialists (16). Recent examination of a pediatric lupus cohort 
from the United Kingdom shows a wide range of presentation time, with some patients 
enduring severe delays of greater than a year (17). However, contributing factors to delays in 
care are still poorly understood and have not been well investigated in other large or diverse 
cohorts around the globe.
In this study, we aimed to examine factors associated with delays to the first pediatric 
rheumatology visit of pediatric lupus patients enrolled in the Childhood Arthritis and 
Rheumatology Research Alliance (CARRA) Legacy Registry, a large and diverse cohort of 
pediatric lupus patients from North America. Evaluating disparities in delays to care is an 
important initial step toward identifying ways to overcome barriers to equitable care and 
improve outcomes for all pediatric lupus patients.
PATIENTS AND METHODS
Study population
Data from the CARRA Legacy Registry for pediatric lupus were examined. The Legacy 
Registry was the initial phase of the CARRA Registry and included 62 sites in North 
America and most pediatric rheumatology centers in the United States. Pediatric lupus 
patients were included in the registry if they had been diagnosed with systemic lupus 
erythematosus (SLE) by a pediatric rheumatologist before the age of 18 and enrolled in the 
registry before the age of 21, to capture childhood-onset SLE and standardize the definition 
of pediatric patients across the sites. Data were collected from the inception of the CARRA 
Legacy Registry in May 2010 through November 2013. Research personnel entered data 
electronically at each CARRA site. De-identified demographic and clinical data from 
baseline registry visits were analyzed. Approval for exemption was obtained from the 
Einstein-Montefiore Institutional Review Board for this study.
Analysis included 598 of the total 988 SLE patients in the registry who were confirmed to 
have met 1997 Revised American College of Rheumatology (ACR) SLE classification 
criteria (18) and who had precise data for date of symptom onset and first visit with a 
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pediatric rheumatologist (Figure 1). Demographic data was obtained from participant and 
parent completed questionnaires. Family medical history, date of symptom onset and date of 
first presentation to a pediatric rheumatologist were obtained from provider questionnaires, 
completed using information from the family and verified by medical records. Estimated 
dates were provided for most patients when exact dates were not available, while 5% (54) of 
patients in the registry had neither precise nor estimated data for symptom onset or for first 
rheumatology visit. To try to maintain the most accurate data, only those participants with 
exact dates were used in our analysis. From these data, the time between symptom onset to 
presentation to a pediatric rheumatologist was calculated.
Demographic information included household income, insurance status, and three-digit zip-
code prefixes for the zip-codes corresponding to where participants were located at symptom 
onset. All registry patients in the analysis were from the United States, including Puerto 
Rico. Three-digit zip-code prefixes were matched to US states and territories based on the 
United States Postal Service data. To define states that had a low density of pediatric 
rheumatologists, state-level data from a previously published Health Resources and Services 
Administration workforce report of the number of pediatric rheumatologists per population 
under 18 (19) was used to determine whether states were below or at and above the median 
density (1 pediatric rheumatologist per 443,800 children).
Statistical analysis
Statistical analysis was performed using Stata 14 (StataCorp, College Station, Texas). The 
time to the first pediatric rheumatology visit was categorized as <1 month (early 
presentation), 1–3 months (typical presentation), 3–12 months (moderate delay), and ≥1 year 
(severe delay). The cut-off for early presentation of ≤1 month was chosen based on prior 
studies that defined patients with “acute onset lupus” as those that were diagnosed within 
one month (20). Of non-early presenters meeting ACR SLE criteria from the CARRA 
Registry, approximately half of the cohort was seen within 3 months and were therefore 
defined as “typical presenters.”
Variable data were examined for normality and nonparametric tests were used when 
applicable. Kruskal-Wallis tests were used for nonparametric continuous variables across the 
categories of presentation time, while Wilcoxon rank sum tests were used for pairwise 
comparisons. Pearson’s chi-square tests and Fisher’s exact tests were used to compare 
categorical variables across different categories of presentation time and for pairwise 
comparisons. Cuzick nonparametric tests for trend were used to examine trends across the 
groups from typical presenters to severely delayed. The four categories of presentation time 
were compared in a multivariable multinomial logistic regression model, where the typical 
presentation (1–3 months) was set as the reference group and factors with p<0.25 from the 
univariable analysis were included. Statistical significance was set to be p<0.05.
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RESULTS
Patient characteristics
The final analysis sample in this present study included 598 patients who met ACR SLE 
classification criteria and had precise data on the times of symptom onset and first pediatric 
rheumatology visit from the total 998 SLE patients in the CARRA Legacy Registry (Figure 
1). Compared to the 598 patients, the excluded patients (either due to missing data on 
precise times of symptom onset or first rheumatology visit, missing data for ACR SLE 
criteria, or not meeting criteria) were more likely to be from low income households, to have 
become symptomatic in a state with a low density of pediatric rheumatologists, and to have 
lower SLE Disease Activity Indices (SLEDAIs) at their first registry visit. The 
characteristics of the 598 included patients are summarized in Table 1. Overall, the median 
age of onset was 13 years (IQR 11, 15), 83% were female, 75% identified as minority race 
and/or ethnicity; 16% were from low income households (while 36% of the total cohort 
reported unknown on income or deferred to answer) and 28% were from states with low 
densities of pediatric rheumatologists when they first became symptomatic.
Median time between onset of symptoms and first seeing a pediatric rheumatologist was 1.4 
months (IQR 7 days, 3.6 months) for included participants. Among them, 262 (44%) were 
seen in ≤1 month, 145 (24%) between 1–3 months, 137 (23%) between 3–12 months, and 54 
(9%) in ≥1 year.
Comparisons of patient characteristics across categories of delay
We compared demographics (Table 1) and clinical characteristics (Table 2) across categories 
of presentation times to see a pediatric rheumatologist. Age at onset (p=0.0003), location in 
a state with a low density of pediatric rheumatologists (p=0.009), SLE family history 
(p=0.02), and proportions of patients meeting immunologic ACR SLE classification criteria 
(p=0.03) were significantly different across the different levels of delay to presentation. 
SLEDAI scores were lower, but not significantly, in patients who presented latest. Variables 
with p<0.25 were included in the subsequent multivariable analysis.
Examining trends across the groups from typical presentation to severe delays, age of onset 
decreased with each level of delay (trend test, p=0.001), as did the likelihood of meeting 
immunologic ACR SLE classification criteria (trend test, p=0.04), while the likelihood of 
coming from a low-income household increased (trend test, p=0.01).
Multivariable multinomial logistic regression model
The multivariable multinomial logistic regression model used typical presentation (1–3 
months) as the reference group and included the following independent variables: age of 
onset, household income, location in a state with a low density of pediatric rheumatologists, 
family history of SLE, having discoid rash, arthritis, immunologic criteria, and neurologic 
ACR SLE classification criteria, and having proliferative lupus nephritis.
Factors contributing to early presentation to a pediatric rheumatologist—Table 
3 shows the comparison between early presenters and typical presenters from the 
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multivariable multinomial logistic regression model. Compared to the reference group of 
patients presenting between 1–3 months, patients with a family history of SLE were more 
likely to present in <1 month (odds ratio (OR) 3.1, 95% confidence interval (CI) 1.0–9.4, 
p=0.04). Patients who lived in a state with a low density of pediatric rheumatologists or met 
criteria for discoid rash were less likely to present early (OR 0.6, 95% CI 0.3–0.9, p=0.02; 
OR 0.5, 95% CI 0.2–1.0, p=0.04, respectively).
Factors contributing to moderate and severe delays in presentation to a 
pediatric rheumatologist—Table 4 shows a comparison between moderately and 
severely delayed presenters and typical presenters from the same multivariable multinomial 
logistic regression model. Patients with proliferative lupus nephritis were less likely to 
present with moderate delays (3–12 months) compared to typical presentation (OR 0.6, 95% 
CI 0.3–1, p=0.048). No other significant factors were noted in this comparison. Severe 
delays were associated with younger age of onset (OR 0.8, 95% CI 0.7–0.9, p<0.001), low 
household income (<$25,000 annual income vs ≥$25,000; OR 2.8, 95% CI 1.1–7.0, p=0.03), 
and a family history of SLE (OR 4.1, 95% CI 1.1–16.1, p=0.04).
DISCUSSION
While most lupus patients in the CARRA Legacy Registry were seen by a pediatric 
rheumatologist within 3 months of symptom onset, moderate delays of 3–12 months were 
seen in 23% of patients, and severe delays of ≥ 1 year were noted in 9%. Contributing 
factors to these delays are likely complex and multifactorial. While individual clinical 
characteristics may influence how quickly patients come to attention or how expedited a 
referral is made, our data show that family and household characteristics, as well as 
accessibility to a pediatric rheumatologist, additionally play an important role.
In this study, earlier age of symptom onset was seen in patients with severe delays to care. 
Perhaps in younger children, lupus was less easily recognized and therefore, took longer to 
present to a pediatric rheumatologist. However, compared to adults, pediatric patients 
present with more fulminant, severe disease (21) and more often present with renal and 
neurologic manifestations (22, 23). Many may require hospitalization, leading to more 
immediate contact with a specialist. This may explain why overall, a shorter median time to 
presentation was seen here in comparison to adult lupus cohorts (7, 24).
Studies in adult lupus have examined accrual time, defined as the time from which a patient 
develops a single ACR SLE criterion to the time at least 4 are met to satisfy diagnostic 
criteria. Accrual time in adult lupus patients is shortened in males (25) and “acute onset 
lupus,” defined as disease with accrual time within one month, is associated with renal 
involvement and worse disease activity (20). Similar to this study, adult patients with discoid 
rash are less likely to present early (20, 24).
However, in contrast to these adult studies, our results suggest that early presentation to a 
pediatric rheumatologist (<1 month) may not be as strongly driven by disease severity. 
While we found that patients with moderate delays were less likely to have proliferative 
lupus nephritis than typically presenting patients (patients seen in 1–3 months); in 
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multivariable testing, neither proliferative lupus nephritis, nor renal manifestations in 
general, were associated with the earliest presenters. Neurologic manifestations, another 
marker of severe disease, also lacked an association with early presentation.
In a sensitivity analysis, we redefined early presentation as <2 weeks and defined severe 
lupus by the presence of ACR neurologic criteria and/or proliferative lupus nephritis to see if 
this was associated with early presentation. Neither decreasing the defining time for early 
presentation nor combining renal and neurologic criteria to define severe disease changed 
our results. Furthermore, disease activity measured by SLEDAI was not significantly 
different across presentation times, nor was it different for earlier presenters compared to 
typical presenters. Finally, because SLEDAI measurements were taken at first registry visit 
and not at initial presentation, in a post-hoc analysis we examined worst ever ACR 
functional class status for registry patients, with the consideration that many patients’ worst 
ever functional status would be upon disease presentation. We found that despite a pattern of 
lower proportions of patients who had ever met class IV (most severely impaired) ACR 
functional status with each level of delay (p trend=0.002), ACR functional status was not a 
significant predictor for any level of delay (or for early presentation) in the multivariable 
regression model.
These results differ from a smaller study of pediatric lupus patients from Croatia, in which 
disease activity was inversely correlated to diagnosis time (26) and a study in the UK in 
which patients with lupus nephritis were more quickly diagnosed (17). However, since our 
study examined time to presentation to a pediatric rheumatologist and not diagnosis, this 
difference may be a result of some ill and acutely presenting patients being first diagnosed 
and treated by other specialists such as nephrologists, immunologists, or adult 
rheumatologists. In a recent survey of pediatricians from a geographically underserved 
section of the US, over a third of respondents reported that they had referred children to 
adult rheumatologists because of either long travel distances or long wait times to see a 
pediatric rheumatologist (27). This problem may be exacerbated in the future, by projected 
worsening shortages in the US pediatric rheumatology workforce over the next decade (28).
Interestingly, a family history of lupus was predictive of both the earliest and latest 
presenters. The association with early presentation can be more easily explained, perhaps 
because parents and providers were more likely to recognize the diagnosis and families may 
have already had relationships with rheumatologists. The association with late presenters 
was unexpected. It may be that these patients were more likely to first be seen by an adult 
rheumatologist, especially if the family was already connected to one. Alternatively, perhaps 
the challenges of caring for lupus within a family inhibited more prompt presentation times 
for an additional family member. While poverty was not associated with a family history of 
lupus, there may be other environmental stressors that confound the relationship between a 
family history of lupus and delayed presentation.
Important findings from this study are the demographic associations observed in the earliest 
and latest presenters. A smaller proportion of early presenters were from a state with a low 
density of pediatric rheumatologists, and a larger proportion of the latest presenters were 
from low-income households. This indicates that access to care and family resources may 
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play a significant role in determining the time it takes a child with lupus to see a pediatric 
rheumatologist.
This is an important distinction from findings from the previous studies from the UK and 
Croatia, in which no association was found between time to see a rheumatologist and 
distance to a pediatric rheumatologist or socioeconomic level (17). It must be noted that the 
UK and Croatia are smaller in area than many states within the US and that distances 
patients traverse may not vary as much as they may in the US. Furthermore, density of 
rheumatologists may be a more sensitive marker for whether an area is underserved because 
it may capture wait times, possibly a more difficult barrier to overcome than distance. In 
regards to the lack of association with socioeconomic level in the European studies, one 
possible explanation for this is differences in health care delivery across economic 
backgrounds in the US in comparison to other countries (29). In contrast, our findings 
support a wealth of research on the importance of demographic and socioeconomic 
disparities when it comes to care of lupus patients in the US, where patients with poor 
healthcare access and low income have worse outcomes (30, 31).
Limited accessibility to pediatric rheumatology specialists in the United States has been well 
described. About a quarter of the pediatric population in the US live further than 80 miles 
from the nearest pediatric rheumatologist (32); pediatric rheumatologists are highly 
concentrated in urban metropolitan areas (16). But access is complex and relates not only to 
geography, volumes in subspecialty clinics, and wait times. Factors within specific health 
systems such as referral patterns likely play a role. Additionally, family resources, 
transportation access, and income all influence how easily a family can travel and take time 
off from work for visits.
One limitation to this study is the reliance on retrospective data available through family 
report and chart review for the date of onset of symptoms to determine time to presentation 
to a pediatric rheumatologist. For the registry database, this information was collected 
through provider questionnaires. Inherent in this design is a potential for inaccuracy in 
reporting. To rely on the most accurate information, we limited this analysis to those registry 
participants who had known specific dates for symptom onset and first pediatric 
rheumatology visit and excluded those with estimated dates. Potential for bias in this study 
includes missing data not at random, highlighted by the fact that patients included and 
excluded in the analysis had important differences in demographics; a large portion of the 
cohort had missing data on income. Analyses including and excluding participants with 
income categorized as “deferred or unknown” did not significantly change the overall results 
in terms of factors associated with delay, and low income remained a significant predictor 
for severe delay.
Further selection bias may exist, if for instance, healthier patients are more likely to agree to 
participate in the registry. However, >50% of patients included in the analysis met ACR SLE 
renal criteria, within the range of what has been described in other pediatric lupus cohorts in 
North America (23, 33). In addition, 18% had severely impaired functioning at some point 
in their illness, meeting ACR functional class IV criteria. These both speak to the significant 
disease burden in the patients that were included in this study.
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As has been pointed out in other studies examining diagnostic delays, the time from 
symptom onset to diagnosis, and ultimately treatment, comprises several intermediate events 
(11, 13). These include the recognition of symptoms by the family, visit to a primary care 
provider, time to referral to a specialist, and time between referral and specialist appointment 
or even, in cases, time between missed appointments to a successfully attended appointment 
with a specialist. While the data used in this study were not granular enough to pinpoint 
which steps in this process were most affected, they suggest that household stressors, such as 
poverty, can lead to delays in the process, as a whole.
The strength of this study is in the large and diverse sample of patients from which data was 
collected through the CARRA Legacy Registry. Thus, we believe the data is representative 
of the experience of pediatric lupus patients in the US and that it sheds light on the 
importance of improving care delivery to children living in poverty and in areas with 
decreased access to pediatric rheumatology. Changes to healthcare access and worsening 
shortages of pediatric rheumatologists in the US may be future hurdles for these patients, 
and may profoundly impact their care. Further identification of specific barriers in between 
symptom development and presentation to a pediatric rheumatologist may lead to 
interventions that minimize severe delays for pediatric lupus patients and improve outcomes.
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SIGNIFICANCE AND INNOVATIONS
• Among pediatric lupus patients enrolled in the CARRA Registry, early 
presentation (<1 month from symptom onset) to a pediatric rheumatologist 
was associated with location in a state with a high density of pediatric 
rheumatologists, a family history of lupus, and the absence of discoid rash.
• Severe delays to care (≥ 1 year) were associated with younger age of onset, a 
family history of lupus, and low income.
Rubinstein et al. Page 11
Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Participants included in secondary data analysis or CARRA SLE Legacy Registry
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Table 3
Multivariable results for factors associated with early presentation to a pediatric rheumatologist in the CARRA 
Lupus Legacy Registry
Early presentation (<1 month)
OR 95% CI p value
Age at onset 1.0 0.9, 1.1 0.65
Household income*
 Low (<$25,000) vs. ≥$25,000 1.3 0.7, 2.6 0.43
 Unknown/deferred vs. ≥$25,000 1.0 0.6, 1.7 0.87
Located in underserved state** 0.6 0.3, 0.9 0.02
SLE family history 3.1 1.0, 9.4 0.04
Discoid ACR SLE criteria 0.5 0.2, 1.0 0.045
Arthritis ACR SLE criteria 0.6 0.3, 1.2 0.17
Neurologic ACR SLE criteria 1.5 0.7, 3.4 0.33
Immunologic ACR SLE criteria 0.7 0.2, 2.2 0.50
Proliferative lupus nephritisƚ 0.9 0.6, 1.5 0.76
Odds ratios (OR), 95% confidence intervals (CI) and p values are results from the multivariable multinomial logistic regression model. Listed in the 
table is the comparison between early presenters (<1 month) and the reference group of patients presenting from 1–3 months.
*Annual household income in US dollars.
**
Located in a state that had less than the median density of pediatric rheumatologists per pediatric population at the time of symptom onset.
ƚ
Proliferative disease determined by World Health Organization Lupus Nephritis Classification: class III and class IV.
Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rubinstein et al. Page 16
Ta
bl
e 
4
M
ul
tiv
ar
ia
bl
e 
re
su
lts
 fo
r f
ac
to
rs
 a
ss
oc
ia
te
d 
w
ith
 m
od
er
at
e 
an
d 
se
v
er
e 
de
la
y 
to
 a
 p
ed
ia
tri
c 
rh
eu
m
at
ol
og
ist
 in
 th
e 
CA
RR
A
 L
up
us
 L
eg
ac
y 
Re
gi
str
y
M
od
er
at
e 
de
la
y 
(3–
12
 m
on
th
s)
Se
v
er
e 
de
la
y 
(≥
 1 
ye
a
r)
O
R
95
%
 C
I
p 
va
lu
e
O
R
95
%
 C
I
p 
va
lu
e
A
ge
 a
t o
ns
et
1.
0
0.
9,
 1
.1
0.
67
0.
8
0.
7,
 0
.9
<
0.
00
1
H
ou
se
ho
ld
 in
co
m
e*
 
Lo
w
 (<
$2
5,0
00
) v
s. 
≥$
25
,00
0
1.
5
0.
7,
 3
.1
0.
34
2.
8
1.
1,
 7
.0
0.
03
 
U
nk
no
w
n
/d
ef
er
re
d 
vs
. ≥
$2
5,0
00
1.
1
0.
6,
 1
.9
0.
81
1.
2
0.
5,
 2
.6
0.
74
Lo
ca
te
d 
in
 u
nd
er
se
rv
ed
 st
at
e*
*
1.
2
0.
7,
 2
.1
0.
47
1.
0
0.
5,
 2
.1
0.
92
SL
E 
fa
m
ily
 h
ist
or
y
2.
6
0.
8,
 8
.5
0.
13
4.
1
1.
1,
 1
6.
1
0.
04
D
isc
oi
d 
AC
R 
SL
E 
cr
ite
ria
1.
0
0.
5,
 2
.1
1.
00
0.
5
0.
1,
 1
.7
0.
25
A
rth
rit
is 
AC
R 
SL
E 
cr
ite
ria
1.
3
0.
7,
 2
.6
0.
47
0.
4
0.
1,
 1
.3
0.
12
N
eu
ro
lo
gi
c 
AC
R 
SL
E 
cr
ite
ria
0.
6
0.
2,
 1
.7
0.
31
0.
3
0,
 2
.4
0.
25
Im
m
un
ol
og
ic
 A
CR
 S
LE
 c
rit
er
ia
0.
3
0.
1,
 1
.0
0.
06
0.
4
0.
1,
 1
.8
0.
24
Pr
ol
ife
ra
tiv
e 
lu
pu
s n
ep
hr
iti
sƚ
0.
6
0.
3,
 1
.0
0.
04
8
0.
7
0.
3,
 1
.5
0.
32
O
dd
s r
at
io
s (
OR
), 9
5%
 co
nfi
de
nc
e 
in
te
rv
al
s (
CI
) a
nd
 p 
va
lu
es
 a
re
 re
su
lts
 fr
om
 th
e 
m
ul
tiv
ar
ia
bl
e 
m
ul
tin
om
ia
l l
og
ist
ic
 re
gr
es
sio
n 
m
od
el
. L
ist
ed
 in
 th
e 
ta
bl
e 
is 
th
e 
co
m
pa
ris
on
 b
et
w
ee
n 
ea
rly
 p
re
se
nt
er
s (
<1
 
m
o
n
th
) a
nd
 th
e r
efe
ren
ce
 gr
ou
p o
f p
ati
en
ts 
pre
sen
tin
g f
rom
 1–
3 m
on
ths
.
*
A
nn
ua
l h
ou
se
ho
ld
 in
co
m
e 
in
 U
S 
do
lla
rs
.
*
*
Lo
ca
te
d 
in
 a
 st
at
e 
th
at
 h
ad
 le
ss
 th
an
 th
e 
m
ed
ia
n 
de
ns
ity
 o
f p
ed
ia
tri
c 
rh
eu
m
at
ol
og
ist
s p
er
 p
ed
ia
tri
c 
po
pu
la
tio
n 
at
 th
e 
tim
e 
of
 sy
m
pt
om
 o
ns
et
.
ƚ P
ro
lif
er
at
iv
e 
di
se
as
e 
de
te
rm
in
ed
 b
y 
W
o
rld
 H
ea
lth
 O
rg
an
iz
at
io
n 
Lu
pu
s N
ep
hr
iti
s C
la
ss
ifi
ca
tio
n:
 c
la
ss
 II
I a
nd
 c
la
ss
 IV
.
Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2019 March 01.
